Evommune, Inc. beat EPS estimates 0% of the time across 3 reported quarters (0 beats, 3 misses), averaging -42.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.68 | $-0.89 | -30.9% | Miss | |
| Q1 FY26 | $-0.81 | not reported | not reported | not reported | |
| Q4 FY25 | $-0.82 | $-1.43 | -74.4% | Miss | |
| Q3 FY25 | $-6.58 | $-8.07 | -22.6% | Miss |
Back to EVMN overview · EVMN holders · EVMN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.